COVID-19 vaccines shown to reduce the likelihood of heart failure and blood clotting following infection

According to a recent study published in the British Medical Journal, COVID-19 vaccines have been shown to reduce the risk of heart failure by up to 55% and blood clots by up to 78% after contracting COVID-19.

After receiving the vaccine, individuals experienced significant health benefits that persisted for up to one year. These positive effects were particularly noticeable immediately following vaccination.

Dr. John Brownstein, chief innovation officer at Boston Children’s Hospital and an ABC News Medical contributor, emphasized that although there has been concern regarding the risk of myocarditis and other thromboembolic events after vaccination, this analysis underscores that the risk of these complications is significantly higher when a person contracts the SARS-CoV-2 infection itself.

In a study conducted in Europe, researchers examined a population of more than 20 million individuals. The participants were divided into two groups: one group received vaccination against the virus, while the other group did not. The vaccines included in the study were Moderna, Pfizer, AstraZeneca, and Johnson & Johnson.

Researchers conducted a study comparing the original strain of the virus with the Delta variant.


According to the researchers’ findings, COVID vaccines have been shown to significantly reduce the risk of blood clots in the veins by 78% within a month of receiving the dose. Additionally, the study found that these vaccines also reduced the risk of blood clots in the arteries by 47% and heart failure by 55%.

According to researchers, getting vaccinated against COVID-19 reduces the risk of developing a blood clot in the vein by 47%, a blood clot in an artery by 28%, and heart failure by 39% within six months of receiving the vaccine.

According to Brownstein, the results of the study provide an important contribution to our understanding of vaccine policy for the future. The findings highlight the significant role that COVID-19 vaccines play in mitigating the risk of long-term health complications after infection.

Adults aged 65 and above now have the opportunity to receive an enhanced COVID-19 vaccine that provides added protection against severe illness, hospitalization, and death. This update comes from the U.S. Centers for Disease Control and Prevention (CDC).

Reference Article

Articles: 2832

Leave a Reply

Your email address will not be published. Required fields are marked *